Fr. 236.00

5-Hydroxytryptamine in Psychiatry - A Spectrum of Ideas

Inglese · Copertina rigida

Spedizione di solito entro 3 a 5 settimane

Descrizione

Ulteriori informazioni










The field of research in 5-hydroxytryptamine has increased dramatically over the past decade, with far reaching implications in psychiatry. The CINP (the international neuropharmacological organization) chose this topic for its first President's Workshop and the record of this meeting is presented here. The contributors are active researchers with a distinguished track record.

Sommario

M. Sandler: Introduction; S. J. Peroutka & A. W. Schmidt: An overview of 5-hydroxytryptamine receptor families; D. L. Murphy: An overview of serotonin neurochemistry and neuroanatomy; M. B. H. Youdim: Milacemide: a neuropsychotropic glycine prodrug that potentiates serotonergic activity; P. C. Waldmeier & L. Maitre: The inactive enantiomer of a noradrenaline uptake blocker reduces 5-HT synthesis; H. Y. Meltzer & R. C. Arora: Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality?; V. Glover, J. Jarman, & M. Sandler: The role of 5-HT in migraine: disentangling the links with depression; G. F. Oxenkrug: The acute effect of monoamine oxidase inhibitors on serotonin conversion to melatonin; G. F. Oxenkrug, P. Requintina, I. M. McIntyre, & R. Davis: Stimulation of rat pineal melatonin synthesis by a single electroconvulsive shock; G. Racagni, D. Tinelli, E. Bianchi, N. Brunello, & J. Perez: cAMP-dependent binding proteins and endogenous phosphorylation after anti-depressant treatment; P. J. Cowen & I. M. Anderson: Abnormal 5-HT neuroendocrine function in depression: association or artefact?; J. Deakin: Experimental tests of the 5-HT imbalance theory of affective disturbance; D. S. Robinson: Antidepressant efficacy of 5-HTO 1A partial agonist drugs; J. J. Lopez-Ibor Jr, J. Saiz-Ruiz, L. Moral, I. Moreno, & R. Vinas: Neuroendocrine serotonergic challenges in clinical research; M. Briley & P. Chopin: Serotonin in anxiety: evidence from animal models; C. Curzon, G. A. Kennett, & P. Whitton: Anxiogenic effect of the 5-HTO1C agonist m - chlorophenylpiperazine; M. Palfreyman & J. H. Kehne: Does 5-hydroxytryptamine have a role in anxiety and the action of anxiolytics?; T. R. Insel: Serotonin in obsessive-compulsive disorder: a casual connection or more monomania about a major monoamine?; M. Linnoila: Monoamines, glucose metabolism, and impulse control; G. Curzon: 5-Hydroxytryptamine in the control of feeding and its possible implications for appetite disturbance; B. Guardiola-Lemaitre: d-Fenfluramine and animal models of eating disorders; C. G. Gottfries: Disturbance of the 5-hydroxytryptamine metabolism in ageing and in Alzheimer's and vascular dementias; M. G. Palfreyman, S. M. Sorenson, A. A. Carr, H. C. Cheng, & M. W. Dudley: 5-HTO3 receptor antagonists and their potential in psychiatric disorders; H. Y. Meltzer: Atypical antipsychotic drugs: the 5HTO2/DAO2 ratio; A. Carlsson: Closing remarks; Index.

Riassunto

The field of research in 5-hydroxytryptamine has increased dramatically over the past decade, with far reaching implications in psychiatry. The CINP (the international neuropharmacological organization) chose this topic for its first President's Workshop and the record of this meeting is presented here. The contributors are active researchers with a distinguished track record.

Testo aggiuntivo

`This is a pleasure to read. The book is well indexed and referenced and each chapter is followed by excellent summaries of the discussions that followed each presentation. This is a `must' for all medical libraries and will be invaluable for any clinical or basic psychopharmacologist who wishes to get up to date with this fascinating area of neurobiology.' Human Psychopharmacology

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.